الاتحاد الأوروبي - الرومانية - EMA (European Medicines Agency)

mylan pharmaceuticals limited - zonisamidă - epilepsie - antiepileptice, - monoterapie în tratamentul crizelor convulsive parțiale, cu sau fără generalizare secundară, la adulți cu epilepsie nou diagnosticată;terapie adjuvantă în tratamentul crizelor convulsive parțiale, cu sau fără generalizare secundară, la adulți, adolescenți și copii cu vârsta de 6 ani și de mai sus.

رومانيا - الرومانية - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

gedeon richter romania s.a. - romania - citalopramum - compr. film. - 20mg - antidepresive inhibitori selectivi ai recaptarii serotoninei

الاتحاد الأوروبي - الرومانية - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - maxim trei din următoarele purificat, inactivat, febra aftoasă, boala tulpini de virus: o1 manisa ≥ 6 pd50*; o1 bfs ≥ 6 pd50*; o taiwan 3/97 ≥ 6 pd50*; a22 iraq ≥ 6 pd50*; a24 cruzeiro ≥ 6 pd50*; o turkey 14/98 ≥ 6 pd50*; asia 1 shamir ≥ 6 pd50*; sat2 saudi arabia ≥ 6 pd50*; * pd50 – 50% protecție doză la bovine așa cum este descris în ph. eur. monografie 0063. - immunologicals - pigs; cattle; sheep - imunizarea activă a bovinelor, ovinelor și porcilor de la vârsta de 2 săptămâni împotriva febrei aftoase pentru reducerea semnelor clinice.

رومانيا - الرومانية - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

gedeon richter romania s.a. - citalopramum - compr. film. - 10mg - antidepresive inhibitori selectivi ai recaptarii serotoninei

رومانيا - الرومانية - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

pfizer manufacturing deutschland gmbh - germania - amlodipinum - compr. - 10mg - bloc. selective canale calciu cu ef. preponderent vascular derivati dihidropiridinici

رومانيا - الرومانية - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

pfizer manufacturing deutschland gmbh - germania - amlodipinum - compr. - 5mg - bloc. selective canale calciu cu ef. preponderent vascular derivati dihidropiridinici

الاتحاد الأوروبي - الرومانية - EMA (European Medicines Agency)

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vaccinuri - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. utilizarea acestui vaccin ar trebui să fie în conformitate cu recomandările oficiale.

الاتحاد الأوروبي - الرومانية - EMA (European Medicines Agency)

pfizer europe ma eeig - respiratory syncytial virus, subgroup a, stabilized prefusion f protein / respiratory syncytial virus, subgroup b, stabilized prefusion f protein - infecții ale virusului sincițial respirator - vaccinuri - abrysvo is indicated for:passive protection against lower respiratory tract disease caused by respiratory syncytial virus (rsv) in infants from birth through 6 months of age following maternal immunisation during pregnancy. vezi secțiunile 4. 2 și 5. active immunisation of individuals 60 years of age and older for the prevention of lower respiratory tract disease caused by rsv. utilizarea acestui vaccin ar trebui să fie în conformitate cu recomandările oficiale.

رومانيا - الرومانية - Ecolab

ecolab deutschland gmbh -

الاتحاد الأوروبي - الرومانية - EMA (European Medicines Agency)

dynavax gmbh - hepatita b antigen de suprafață - hepatita b - vaccinuri - heplisav b is indicated for the active immunisation against hepatitis b virus infection (hbv) caused by all known subtypes of hepatitis b virus in adults 18 years of age and older. the use of heplisav b should be in accordance with official recommendations. it can be expected that hepatitis d will also be prevented by immunisation with heplisav b as hepatitis d (caused by the delta agent) does not occur in the absence of hepatitis b infection.